{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:44:51Z","timestamp":1791546291423,"version":"4.3.4"},"reference-count":61,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2025,11,29]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To provide a practical, pathology-centred overview of Claudin 18.2 as a biomarker and therapeutic target, covering biology, assay methods and interpretation, pre-analytical factors, clinicopathological associations and implications for treatment selection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We performed a narrative review of the biomedical and pathology literature on\n                      <jats:italic>CLDN18<\/jats:italic>\n                      \/Claudin 18.2, including basic science, translational studies, immunohistochemistry (IHC) and in situ assays, and clinical trials of Claudin 18.2-directed therapies. Reference lists were hand-searched to capture additional relevant reports. Emphasis was placed on data informing routine diagnostic practice (expression patterns, scoring, fixation variables, pitfalls).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Claudin 18.2 localises to tight junctions of differentiated gastric epithelium and is aberrantly expressed in gastric and gastro-oesophageal junction adenocarcinomas, with variable expression reported in pancreatic, biliary and other tumours. Loss or dysregulation of Claudin 18.2 contributes to tumour progression via disruption of epithelial integrity and activation of oncogenic pathways; infection-related and inflammation-related downregulation is described in gastric mucosa. For IHC, clone selection, tissue handling, fixation time and membrane-dominant scoring critically affect results; common pitfalls include cytoplasmic staining and heterogeneity. Claudin 18.2 expression shows predictive value for targeted agents under clinical use\/evaluation, supporting its role as a companion biomarker. Reporting recommendations include membrane intensity\/percentage thresholds and clear documentation of pre-analytical conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Claudin 18.2 is a biologically plausible and clinically actionable biomarker. Robust pre-analytical handling, validated IHC protocols and standardised scoring are essential for reliable patient selection. Wider adoption of harmonised methods and further disease-specific studies will refine cut-offs, clarify prognostic value and optimise integration of Claudin 18.2-directed therapies into routine care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jcp-2025-210328","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T18:20:20Z","timestamp":1765995620000},"page":"148-160","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Claudin 18.2 in cancer research and treatment: a pathologist\u2019s perspective"],"prefix":"10.1136","volume":"79","clinical-trial-number":[{"clinical-trial-number":"nct03504397","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03653507","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4492-9237","authenticated-orcid":false,"given":"Gurzhikhan","family":"Murtazaalieva","sequence":"first","affiliation":[{"name":"Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Baldwin","sequence":"additional","affiliation":[{"name":"Pathology Liaison, Roche Diagnostics Corporation, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Fassan","sequence":"additional","affiliation":[{"name":"Pathology, Padua University Hospital, Padua, Veneto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4230-9308","authenticated-orcid":false,"given":"Vikram","family":"Deshpande","sequence":"additional","affiliation":[{"name":"Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"2026021902550848000_79.3.148.1","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/PAS.0000000000001847","article-title":"Claudin-18 as a Promising Surrogate Marker for Endocervical Gastric-type Carcinoma","volume":"46","author":"Kiyokawa","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"2026021902550848000_79.3.148.2","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1016\/j.bpj.2024.06.010","article-title":"Biophysics of claudin proteins in tight junction architecture: Three decades of progress","volume":"123","author":"Marsch","year":"2024","journal-title":"Biophys J"},{"key":"2026021902550848000_79.3.148.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00874-2"},{"key":"2026021902550848000_79.3.148.4","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.21.21.7380-7390.2001"},{"key":"2026021902550848000_79.3.148.5","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2024.5424","article-title":"Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer (Review)","volume":"54","author":"Katoh","year":"2024","journal-title":"Int J Mol Med"},{"key":"2026021902550848000_79.3.148.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2011.04.007"},{"key":"2026021902550848000_79.3.148.7","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1097\/PAS.0000000000001583","article-title":"Claudin-18 as a Marker for Identifying the Stomach and Pancreatobiliary Tract as the Primary Sites of Metastatic Adenocarcinoma","volume":"44","author":"Li","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"2026021902550848000_79.3.148.8","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-019-02624-7"},{"key":"2026021902550848000_79.3.148.9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1596460","article-title":"Tight junctional protein family, Claudins in cancer and cancer metastasis","volume":"15","author":"Ji","year":"2025","journal-title":"Front Oncol"},{"key":"2026021902550848000_79.3.148.10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1051497","article-title":"The role and mechanism of claudins in cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"2026021902550848000_79.3.148.11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14020290","article-title":"Claudins and Gastric Cancer: An Overview","volume":"14","author":"Hashimoto","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026021902550848000_79.3.148.12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1132319"},{"key":"2026021902550848000_79.3.148.13","doi-asserted-by":"crossref","first-page":"11411","DOI":"10.3748\/wjg.v21.i40.11411","article-title":"Tight junction disruption: Helicobacter pylori and dysregulation of the gastric mucosal barrier","volume":"21","author":"Caron","year":"2015","journal-title":"World J Gastroenterol"},{"key":"2026021902550848000_79.3.148.14","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.08.041"},{"key":"2026021902550848000_79.3.148.15","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyz068"},{"key":"2026021902550848000_79.3.148.16","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13919"},{"key":"2026021902550848000_79.3.148.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0508-4"},{"key":"2026021902550848000_79.3.148.18","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-024-01518-1"},{"key":"2026021902550848000_79.3.148.19","first-page":"2995","article-title":"Immunohistochemical study of claudin 18 involvement in intestinal differentiation during the progression of intraductal papillary mucinous neoplasm","volume":"30","author":"Sanada","year":"2010","journal-title":"Anticancer Res"},{"key":"2026021902550848000_79.3.148.20","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02380-0"},{"key":"2026021902550848000_79.3.148.21","doi-asserted-by":"publisher","DOI":"10.1369\/jhc.2009.953810"},{"key":"2026021902550848000_79.3.148.22","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10120-025-01609-7","article-title":"Heterogeneity of predictive biomarker expression in gastric and esophago-gastric junction carcinoma with peritoneal dissemination","volume":"28","author":"Angerilli","year":"2025","journal-title":"Gastric Cancer"},{"key":"2026021902550848000_79.3.148.23","doi-asserted-by":"crossref","first-page":"100491","DOI":"10.1016\/j.modpat.2024.100491","article-title":"Gastric Carcinoma in Autoimmune Gastritis: A Histopathologic and Molecular Study","volume":"37","author":"Angerilli","year":"2024","journal-title":"Mod Pathol"},{"key":"2026021902550848000_79.3.148.24","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11111095","article-title":"Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas","volume":"11","author":"Pellino","year":"2021","journal-title":"J Pers Med"},{"key":"2026021902550848000_79.3.148.25","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-024-01505-6"},{"key":"2026021902550848000_79.3.148.26","doi-asserted-by":"publisher","DOI":"10.14670\/HH-18-477"},{"key":"2026021902550848000_79.3.148.27","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2025.14886","article-title":"Claudin 18.2: An attractive marker in pancreatic ductal adenocarcinoma","volume":"29","author":"Valentini","year":"2025","journal-title":"Oncol Lett"},{"key":"2026021902550848000_79.3.148.28","doi-asserted-by":"publisher","DOI":"10.1136\/jcp-2023-209268"},{"key":"2026021902550848000_79.3.148.29","doi-asserted-by":"publisher","DOI":"10.1111\/his.13797"},{"key":"2026021902550848000_79.3.148.30","doi-asserted-by":"crossref","unstructured":"Ni S-J , Wang X , Yuan L , et al . Claudin18.2 expression in gallbladder cancer correlates with immune activation and a favourable prognosis. J Clin Pathol 2025. doi:10.1136\/jcp-2024-209914","DOI":"10.1136\/jcp-2024-209914"},{"key":"2026021902550848000_79.3.148.31","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00428-024-03896-4","article-title":"Variability in morphology and immunohistochemistry of Crohn\u2019s disease-associated small bowel neoplasms: implications of Claudin 18 and Cadherin 17 expression for tumor-targeted immunotherapies","volume":"486","author":"Iwaya","year":"2025","journal-title":"Virchows Arch"},{"key":"2026021902550848000_79.3.148.32","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-022-03393-6"},{"key":"2026021902550848000_79.3.148.33","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-024-03756-1"},{"key":"2026021902550848000_79.3.148.34","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/PAS.0000000000002342","article-title":"Claudin-18 and Mutation Surrogate Immunohistochemistry in Gastric-type Endocervical Lesions and their Differential Diagnoses","volume":"49","author":"Lin","year":"2025","journal-title":"Am J Surg Pathol"},{"key":"2026021902550848000_79.3.148.35","doi-asserted-by":"crossref","first-page":"559","DOI":"10.5858\/arpa.2021-0428-OA","article-title":"Claudin-18","volume":"147","author":"Wong","year":"2022","journal-title":"Arch Pathol Lab Med"},{"key":"2026021902550848000_79.3.148.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100589"},{"key":"2026021902550848000_79.3.148.37","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40618-023-02245-7","article-title":"Claudin 18.2 expression in digestive neuroendocrine neoplasms: a clinicopathological study","volume":"47","author":"Jiang","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"2026021902550848000_79.3.148.38","doi-asserted-by":"crossref","first-page":"155537","DOI":"10.1016\/j.prp.2024.155537","article-title":"Expression profiles of cadherin 17 and claudin 18.2 in comparison with peptide hormonal expression in pancreatic neuroendocrine tumours: Implications for targeted immunotherapy","volume":"262","author":"Maeda","year":"2024","journal-title":"Pathol Res Pract"},{"key":"2026021902550848000_79.3.148.39","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2021.1967080","article-title":"Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials","volume":"10","author":"Kyuno","year":"2022","journal-title":"Tissue Barriers"},{"key":"2026021902550848000_79.3.148.40","doi-asserted-by":"crossref","first-page":"100284","DOI":"10.1016\/j.labinv.2023.100284","article-title":"Global Ring Study to Investigate the Comparability of Total Assay Performance of Commercial Claudin 18 Antibodies for Evaluation in Gastric Cancer","volume":"104","author":"Jasani","year":"2024","journal-title":"Lab Invest"},{"key":"2026021902550848000_79.3.148.41","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02465-7"},{"key":"2026021902550848000_79.3.148.42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.9807"},{"key":"2026021902550848000_79.3.148.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2017.01.011"},{"key":"2026021902550848000_79.3.148.44","unstructured":"Roche Tissue Diagnostics . VENTANA CLDN18 (43-14A) RxDx Assay: Physician Labeling. 2024."},{"key":"2026021902550848000_79.3.148.45","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2023-0483-CP"},{"key":"2026021902550848000_79.3.148.46","doi-asserted-by":"crossref","first-page":"100712","DOI":"10.1016\/j.modpat.2025.100712","article-title":"Claudin 18.2 Expression in 1404 Digestive Tract Adenocarcinomas Including 1175 Colorectal Carcinomas: Distinct Colorectal Carcinoma Subtypes Are Claudin 18.2 Positive","volume":"38","author":"McHugh","year":"2025","journal-title":"Mod Pathol"},{"key":"2026021902550848000_79.3.148.47","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"The Lancet"},{"key":"2026021902550848000_79.3.148.48","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-024-01595-w","article-title":"Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting","volume":"17","author":"Zhou","year":"2024","journal-title":"J Hematol Oncol"},{"key":"2026021902550848000_79.3.148.49","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat Med"},{"key":"2026021902550848000_79.3.148.50","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-23-0353"},{"key":"2026021902550848000_79.3.148.51","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2023.41.16_suppl.3016","article-title":"First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant\/refractory solid tumors","volume":"41","author":"Wang","year":"2023","journal-title":"JCO"},{"key":"2026021902550848000_79.3.148.52","doi-asserted-by":"crossref","unstructured":"Kwak Y , Kim T-Y , Nam SK , et al . Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression. Oncologist 2025;30. doi:10.1093\/oncolo\/oyae238","DOI":"10.1093\/oncolo\/oyae238"},{"key":"2026021902550848000_79.3.148.53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00602"},{"key":"2026021902550848000_79.3.148.54","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.3_suppl.TPS260","article-title":"Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G\/GEJ)\u2014ILUSTRO Cohort 3","volume":"39","author":"Klempner","year":"2021","journal-title":"JCO"},{"key":"2026021902550848000_79.3.148.55","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00543","article-title":"Retrospective Study of Claudin 18 Isoform 2 Prevalence and Prognostic Association in Gastric and Gastroesophageal Junction Adenocarcinoma","volume":"8","author":"Waters","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"2026021902550848000_79.3.148.56","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-022-00385-1","article-title":"Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy","volume":"10","author":"Cao","year":"2022","journal-title":"Biomark Res"},{"key":"2026021902550848000_79.3.148.57","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28400"},{"key":"2026021902550848000_79.3.148.58","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.21037\/tcr-19-1876","article-title":"Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer","volume":"9","author":"Hong","year":"2020","journal-title":"Transl Cancer Res"},{"key":"2026021902550848000_79.3.148.59","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/his.14358","article-title":"Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy","volume":"79","author":"Iwaya","year":"2021","journal-title":"Histopathology"},{"key":"2026021902550848000_79.3.148.60","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.2010.02587.x"},{"key":"2026021902550848000_79.3.148.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100569"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp-2025-210328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T10:55:55Z","timestamp":1771498555000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp-2025-210328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":61,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2,19]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/jcp-2025-210328"],"URL":"https:\/\/doi.org\/10.1136\/jcp-2025-210328","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]}}}